Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection

被引:114
作者
Warfield, KL [1 ]
Olinger, G [1 ]
Deal, EM [1 ]
Swenson, DL [1 ]
Bailey, M [1 ]
Negley, DL [1 ]
Hart, MK [1 ]
Bavari, S [1 ]
机构
[1] USA, Med Res Inst Infect Dis, Frederick, MD 21702 USA
关键词
D O I
10.4049/jimmunol.175.2.1184
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Ebola virus (EBOV)-like particles (eVLP), composed of the EBOV glycoprotein and matrix viral protein (VP)40 with a lipid membrane, are a highly efficacious method of immunization against EBOV infection. The exact requirements for immunity against EBOV infection are poorly defined at this time. The goal of this work was to determine the requirements for EBOV immunity following eVLP vaccination. Vaccination of BALB/c or C57BL/6 mice with eVLPs in conjunction with QS-21 adjuvant resulted in mixed IgG subclass responses, a Th1-like memory cytokine response, and protection from lethal EBOV challenge. Further, this vaccination schedule led to the generation of both CD4(+) and CD8(+) IFN-gamma(+) T cells recognizing specific peptides within glycoprotein and VP40. The transfer of both serum and splenocytes, but not serum or splenocytes alone, from eVLP-vaccinated mice conferred protection against lethal EBOV infection in these studies. B cells were required for eVLP-mediated immunity to EBOV because B cell-deficient mice vaccinated with eVLPs were not protected from lethal EBOV challenge. We also found that CD8(+), but not CD4(+), T cells are absolutely required for eVLP-mediated protection against EBOV infection. Further, eVLP-induced protective mechanisms were perforin-independent, but IFN-gamma-dependent. Taken together, both EBOV-specific Immoral and cytotoxic CD8(+) T cell responses are critical to mediate protection against filoviruses following eVLP vaccination.
引用
收藏
页码:1184 / 1191
页数:8
相关论文
共 48 条
[1]   Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients [J].
Baize, S ;
Leroy, EM ;
Georges-Courbot, MC ;
Capron, M ;
Lansoud-Soukate, J ;
Debré, P ;
Fisher-Hoch, SP ;
McCormick, JB ;
McCormick, JB ;
Georges, AJ .
NATURE MEDICINE, 1999, 5 (04) :423-426
[2]   Lipid raft microdomains: A gateway for compartmentalized trafficking of Ebola and Marburg viruses [J].
Bavari, S ;
Bosio, CM ;
Wiegand, E ;
Ruthel, G ;
Will, AB ;
Geisbert, TW ;
Hevey, M ;
Schmaljohn, C ;
Schmaljohn, A ;
Aman, MJ .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (05) :593-602
[3]  
Boisgerault Florence, 2002, Expert Rev Vaccines, V1, P101, DOI 10.1586/14760584.1.1.101
[4]   A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever [J].
Bray, M ;
Davis, K ;
Geisbert, T ;
Schmaljohn, C ;
Huggins, J .
JOURNAL OF INFECTIOUS DISEASES, 1999, 179 :S248-S258
[5]  
Brown DWG, 1997, REV MED VIROL, V7, P239, DOI 10.1002/(SICI)1099-1654(199712)7:4&lt
[6]  
239::AID-RMV210&gt
[7]  
3.0.CO
[8]  
2-Q
[9]   The evolving field of biodefence: Therapeutic developments and diagnostics [J].
Burnett, JC ;
Henchal, EA ;
Schmaljohn, AL ;
Bavari, S .
NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (04) :281-297
[10]  
Estes MK, 1997, ADV EXP MED BIOL, V412, P387